An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company wanted to use its proprietary technology to validate small molecule assets targeting distinct biological targets with a high degree of specificity. These assets ranged in developmental stage from 6-9 months pre-IND through Phase 1. The company was agnostic as to which indications the assets were developed for and hoped to develop their desired asset for a CNS indication. They engaged Alacrita to identify other potential partners and assets, with a particular focus in the US and Europe.
Alacrita conducted a comprehensive search of assets that had a good fit with the target company's therapeutic focus and clinical development stage. We generated a long list of potential opportunities and, based on iterative discussions with our client, we filtered the database to yield a list of ~50 potential opportunities that represented the best combination of fit and potential availability. From this list, we prioritized outreach based on how well each opportunity met the criteria of our client.
We regularly consult with clients developing CNS therapeutics, as well as advise investors and BD teams on individual assets, pipelines and companies in this field. For more details on our expertise, please visit the below page or reach out.
Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.